Democratic leaders of the House Energy and Commerce Committee today from their investigation of 14 companies that sell or help consumers sign up for short-term, limited duration health plans.

Among other findings, they said all eight plans they investigated deny claims for pre-existing conditions; that most of them 鈥渟ystematically exclude coverage for most major medical conditions resulting from pre-existing conditions鈥; and that the average broker commission for the plans they investigated was 23% compared with 2% for Affordable Care Act-compliant plans in 2018.

They also said that less than half of the premium dollars collected from consumers are spent on medical care, unlike ACA-compliant individual market plans, which are required to spend at least 80% of premium dollars on health care; and that enrollment in the plans rose 27% in 2019 to about 3 million consumers.

In addition, they said consumers who purchase this type of health plan are more likely to have substantial out-of-pocket medical costs due to the lack of coverage provided by these companies.

Related News Articles

Headline
The U.S. Departments of Labor, Health and Human Services, and the Treasury announced Aug. 7 that they are reconsidering the definition of short-term, limited-鈥
Headline
A new analysis published Aug. 6 by the Peterson Center on Healthcare and KFF found that Health Insurance Marketplace insurers will propose a median premium鈥
Headline
The Senate Appropriations Committee July 31 advanced the fiscal year 2026 appropriations bill for the Departments of Labor, Health and Human Services,鈥
Perspective
House members are back in their districts for the August recess and senators are likely to return to their states soon.While lawmakers are home, it鈥檚 important鈥
Headline
The Trump administration today announced steps drug manufacturers must take to lower prescription drug prices in the U.S. to "most favored nation" pricing, the鈥
Headline
The Department of Health and Human Services today issued a notice announcing a 340B Rebate Model Pilot Program as a voluntary mechanism for qualifying drug鈥